Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
Content archived on 2024-05-28

Priorities and Standards in Pharmacogenomic Research: Opportunities for a Safer and More Efficient Pharmacotherapy

Objective

Pharmacogenomics is the scientific discipline that relates inter-individual variation in drug response to genetic variation. While there have been major advances in basic genomic knowledge and genotyping technologies, translation into clinical practice has been slow. It is essential we quicken the pace of translational research in pharmacogenomics - at present, we cannot define which patients are going to respond to drugs, and which patients are going to develop adverse drug reactions. In this ITN, our concerted action across the EU, in cooperation with US researchers will train young investigators and clinicians (14 ESR and 2 ER) to establish, evaluate and retrieve relevant genetic information from patients, and relate it to clinical outcomes of drug therapy. This will be achieved through sharing patient materials, performing pooled analyses, transfer of knowledge and skills across laboratories and provide access to high-throughput technology platforms between 5 academic (3 EU, 1 ICPC, 1 OTC partners) and 4 industry partners (3 EU, 1AC partner). This will enhance translational research, promote uniform drug treatment standards throughout Europe and worldwide, and improve the competitiveness of the EU in this emerging and exciting field.

Fields of science (EuroSciVoc)

Keywords

Topic(s)

Call for proposal

FP7-PEOPLE-ITN-2008
See other projects for this call

Funding Scheme

MC-ITN - Networks for Initial Training (ITN)

Coordinator

ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG MBH
EU contribution
€ 1 270 261,00
Address
AUERBACHSTRASSE 112
70376 Stuttgart
Germany
Region
Baden-Württemberg Stuttgart Stuttgart, Stadtkreis
Activity type
Research Organisations
Links
Total cost
No data

Participants (6)